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Apoptosis is a fundamental biological process involved in
embryogenesis, morphogenesis and tumour regression (Kerr et al,
1972; Wyllie et al, 1980). Recent observations suggest that modu-
lation of protein phosphorylation (Gjertsen and Døskeland, 1995)
and activation of cellular proteases are important factors regu-
lating this type of cell death (reviewed in Zhivotovski et al,
1995; Golstein, 1997). The role of protein phosphorylation in
regulation of apoptosis and activation of the downstream cascade
of cystein proteases (caspases) is poorly understood. Inhibitors of
serine/threonine protein phosphatases, like okadaic acid (OA),
have proved useful to elucidate cellular functions regulated by
phosphorylation (Cohen et al, 1990). OA, preferentially inhibiting
type 2A protein phosphatases (Bialojan and Takai, 1988), induces
swift and synchronous apoptotic cell death in various cell types
(Bøe et al, 1991; Gjertsen et al, 1994; Kiguchi et al, 1994).
The caspase family of cell death proteases (Alnemri et al, 1996)
is involved in the execution of apoptosis in mammalian cells
(reviewed in Cohen, 1997). Less is known about their role in
the triggering of apoptosis or whether this hierarchy of proteases
may have separate functions in various types of cells. More specif-
ically, the role of protein phosphorylation in regulation of apop-
tosis and activation of the downstream cascade of cystein
proteases (caspases) is poorly understood. We have previously
reported that the cytosolic protease inhibitor, plasminogen acti-
vator inhibitor type 2 (PAI-2), is specifically cleaved during
OA-induced cell death in a promyelocytic leukaemic cell line and
in myeloid leukaemic cells isolated from sternal bone marrow of
patients suffering from leukaemia (Jensen et al, 1994). In fibrosar-
coma cells and HeLa cells, transfected with PAI-2 expression
vectors, PAI-2 was found to have a cytoprotective effect on tumour
necrosis factor alpha (TNF-a)-induced apoptosis (Kumar and
Baglioni, 1991; Dickinson et al, 1995). In this regard PAI-2 is
similar to the cowpox viral serine protease inhibitor CrmA, which
abrogates apoptosis by inhibiting proteases of the caspase family
(Ray et al, 1992) and granzyme B (Quan et al, 1995). However,
PAI-2 reacts with Arg-specific proteases and not Asp-specific
proteases like CrmA (Jensen, 1997). Recent observations,
showing that PAI-2 interacts with cytosolic proteins through a
domain localized between helices C and D (Jensen et al, 1996;
Dickinson et al, 1998), suggest that not only its protease inhibitory
function, but also its subcellular targeting could be important for
its cellular function.
The aim of the present study was to test the role of protease
activation during OA-induced apoptosis, and to define whether
caspases are part of the proteolytic pathway leading to the apop-
tosis-associated PAI-2 cleavage. Secondly, to determine the event
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Summary We have previously reported that the putative cytoprotective protease inhibitor, plasminogen activator inhibitor type 2 (PAI-2), is
specifically cleaved during okadaic acid-induced apoptosis in a myeloid leukaemic cell line (Br J Cancer (1994) 70: 834–840). HL-60 cells
exposed to okadaic acid and camptothecin underwent morphological and biochemical changes typical of apoptosis, including
internucleosomal DNA fragmentation and PAI-2 cleavage. Significant endogenous PAI-2 cleavage was observed 9 h after exposure to
okadaic acid; thus correlating with other signs of macromolecular degradation, like internucleosomal DNA fragmentation. In camptothecin-
treated cells, PAI-2 cleavage was an early event, detectable after 2 h of treatment, and preceding internucleosomal DNA fragmentation. The
caspase I selective protease inhibitor, YVAD-cmk, inhibited internucleosomal DNA fragmentation and PAI-2 cleavage of okadaic acid and
camptothecin-induced apoptotic cells. YVAD-cmk rather sensitively and non-toxically inhibited camptothecin-induced morphology, but not
okadaic acid-induced morphology. In in vitro experiments recombinant PAI-2 was not found to be a substrate for caspase I. The results
suggest that caspase I selective protease inhibition could antagonize parameters coupled to the execution phase of okadaic acid- and
camptothecin-induced apoptosis, but not the commitment to cell death.
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changes in morphology, nuclear chromatin structure, and inter-
nucleosomal DNA fragmentation. Camptothecin, a topoisomerase
I inhibitor (reviewed in Rothenberg, 1997), was included in the
study as an independent inducer of apoptosis (Del Bino et al, 1992;
Shimizu and Pommier, 1997). We report that, although morpho-
logical and biochemical parameters of apoptosis, including PAI-2
cleavage, could be blocked by protease inhibition, the time course
for commitment to cell death was not prolonged. The effect of
protease inhibitors on OA and camptothecin-induced cell death,
including PAI-2 cleavage, thus reflects more the inhibition of
specific parts of the apoptotic process, e.g. the macromolecular
breakdown, than the inhibition of cell death itself.
MATERIALS AND METHODS
Materials
Okadaic acid was from LC Services Corporation (Woburn, MA,
USA). Camptothecin, dimethylsulphoxide (DMSO) and bisbenz-
imide (Hoechst 33342), were from Sigma (St Louis, MO, USA).
YVAD (Ac-Tyr-Val-Ala-Asp-chloromethylketone) and Z-VAD
fmk (N-benzyloxycarbony-Val-Ala-Asp (O-methyl)-fluoro-
methylketone were from Bachem Bioscience Inc. (Bubendorff,
Switzerland). [125I] (carrier free) was purchased from Amersham
(Little Chalfont, UK). ECL immunoassay signal reagents and
Hyperfilm MP were from Amersham (Little Chalfont, UK). We
thank Drs Graeme Woodrow (Biotech Australia), Remy Sadoul
(Glaxo Molecular Biology Laboratory, Geneva, Switzerland) and
Winnie Wong (BASF Bioresearch Corporation, Worcester, MA,
USA) for the kind gifts of recombinant human PAI-2, recombinant
human proIL-1b and rabbit anti-proIL-1b serum and recombinant
human ICE respectively.
Cell culturing and handling of cells
The HL-60 cells were cultured in a I:I medium of RPMI and
Dulbecco’s modified Eagle’s medium (DMEM; Sigma, St Louis,
MO, USA) supplemented with 10% fetal calf serum (FCS;
Biochrom KG, Germany), 2 mM glutamin, 100 IU ml-1 penicillin
and 100 m ml-1 streptomycin. In all experiments cells in loga-
rithmic growth were seeded at a density of 4 ´ 105 per ml and kept
below 10 ´ 105 per ml during the experimental period for optimal
growth conditions. The various substances added to the cultures
were dissolved in DMSO. The concentration of DMSO was
routinely kept below 0.1% and shown not to interfere with cell
survival. The cells were free of mycoplasma and other infections.
In studies, aimed at testing the commitment to cell death after
exposure to various substances, cell aliquots were quenched in 10
volumes of culture medium, spun (700 ´ gav. for 5 min), and
washed twice in complete medium before reseeding, ensuring a
theoretical 3000-fold dilution of added substances.
Nuclear chromatin condensation assay
Aliquots of variously treated HL-60 cells were fixed in 2%
glutaraldehyde in 0.1 M Na-cacodylate buffer (pH 7.4) supple-
mented with the DNA-specific fluorochrome, bisbenzimide. The
nuclear chromatin condensation was determined as previously
described (Bøe et al, 1995). Normal (non-apoptotic) cells had a
uniform vague nuclear fluorescence, whereas apoptotic cells
showed an increased fluorescence from condensed non-fragmented
(OA-treated cells) or fragmented (camptothecin-treated cells)
nuclei; the latter were easily distinguished from mitotic cells. Few
cells emitted an intermediate fluorescence pattern. Normal and
apoptotic cells were found to exclude trypan blue (0.2%), in
contrast to necrotic cells.
Electron microscopy
HL-60 cells (3 ´ 105 cells) were fixed at 37°C in 0.1 M Na-cacody-
late buffer, pH 7.4 containing 2% glutaraldehyde and placed on ice
for 15 min. The samples were subsequently rinsed three times in
0.1 M Na-cacodylate buffer and post-fixed in buffer containing 1%
OsO4. The cells were then dehydrated, embedded in resin,
sectioned and stained with uranyl acetate and lead citrate as pre-
viously described (Bøe et al, 1991). The specimens were examined
in a Jeol 100CX electron microscope. The microphotographs were
digitalized using an AGFA Arcus II scanner and processed by
Adobe Photoshop software.
DNA-fragmentation assay
Cell pellets containing 3 ´ 106 cells were dissolved in 0.5 ml cell
lysis buffer (100 mM EDTA, 10 mM EGTA, 0.5% sodium dodecyl
sulphate (SDS), 10 mM Tris-HCl, pH 8.0), and subsequently
treated with 30 mg ml-1 RNAase and 100 mg ml-1 protease K,
extracted in 10 mM Tris-buffered phenol, pH 8.0, washed twice in
70% ethanol, air dried and re-dissolved in 10 mM Tris-HCl, 1 mM
EDTA, pH 7.5 as described elsewhere (Gjertsen et al, 1994). DNA
aliquots (10 mg) were electrophoresed in 1.5% agarose gels and
visualized under UV illumination after staining with 0.5 mg ml-1
ethidium bromide. The ratio of high molecular weight (HMW)
DNA (above 8.5 kb) versus low molecular weight (LMW) DNA
(0.1–7.2 kb) was determined by densiometric measurement of the
negative Polaroid 665 film using a LKB Ultroscan XL laser
densiometer as described previously (Gjertsen et al, 1994).
In vivo PAI-2 cleavage
For determination of PAI-2 cleavage 2 ´ 106 cells were centrifuged
(1000 ´ gav. for 5 min) and dissolved in PAI-2 lysis buffer (120 mM
NaCl, 50 mM HePes, pH 7.4, 5 mM EDTA, 3 mM EGTA,
0.05 mg ml-1 aprotinin, 1 mg ml-1 soybean trypsin inhibitor, 2 mM
phenylmethane-sulphonylfluoride, 0.5 mM dithioerythritol, 250
mM sucrose, 1% Triton X-100 (all from Sigma, St. Louis, MO,
USA, except when noted) at a concentration of approximately 1.5
´ 107 per ml. The lysate was homogenized by three strokes for 5 s
in an Ultra Turax homogenizer, aliquoted and snap frozen in liquid
nitrogen. The samples were stored at – 80°C. Cell extracts corre-
sponding to 0.5 ´ 106 cells were loaded in each slot of a reducing
8–16% gradient SDS-polyacrylamide gel (PAGE) (Jensen et al,
1990), resolved and electroblotted onto polyvinylidene fluoride
membranes. The residual protein-binding capacity was quenched
by 2% skimmed milk, 0.5% Tween-20 in phosphate-buffered
saline (PBS) (quenching buffer) and probed with the monoclonal
anti-PAI-2 antibody (#3750, Amersham Diagnostics) diluted
1/350 in quenching buffer. Bound antibody was detected using the
ECL immunoassay signal reagents and Hyperfilm MP.
In vitro ICE-cleavage assay
Recombinant human IL-1b (30 mg ml-1) and PAI-2 (60 mg ml-1)
were incubated in the absence or presence of recombinant human
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thritol, 0.5 mM EDTA, 20% glycerol. The samples were added
equal volumes 2 ´ reducing SDS-electrophoresis sample buffer
and resolved by 10–20 gradient SDS-PAGE. The gel was analysed
by immunoblotting as described above except for the detection of
interleukin (IL)-1b, which was performed using rabbit anti-human
IL-1b diluted 1/500. The bound antibodies were detected as
mentioned above.
RESULTS
Apoptosis induced by okadaic acid and camptothecin
differs phenotypically in HL-60 cells
OA-induced cell death in HL-60 cells was characterized by an
early loss of microvilli, pronounced blebbing of the plasma
membrane, cytosolic vacuolization beneath the plasma membrane
and segregation of subcellular organelles forming interconnected
clusters of membrane-bound organelles (Figure 1B). The major
cytosolic effects rather closely paralleled the onset of nuclear chro-
matin condensation. The time course for the transition from
apparent normal (non-condensed) to markedly condensed nuclear
chromatin was swift, rendering few cells in the transitional state.
Exposure of HL-60 cells to 300 nM OA-induced nuclear chromatin
condensation in more than 90% of the cells within 6 h (Figure 2)
strongly favouring this process to be independent of cell cycle
phase. On exposure to lower OA concentration cell death was
induced less synchronously; thus only half the cells were morpho-
logically affected after challenging with 100 nM OA for 12 h.
Apoptosis induced by camptothecin occurred more swiftly, but less
synchronously, than with OA and was characterized with a
pronounced formation of membrane-encapsulated apoptotic bodies
and extensive nuclear fragmentation (Figure 1C, Figure 3). All
early phase apoptotic cells excluded trypan blue suggesting that the
integrity of the plasma membranes remained intact in these cells.
Okadaic acid- and camptothecin-induced apoptosis is
sensitive to protease inhibition by YVAD-cmk and
Z-VAD-fmk but differs phenotypically
The peptide inhibitors, YVAD-cmk and Z-VAD-fmk, known to
affect the caspase cascade of proteases involved in apoptosis, were
tested for their ability to modulate OA- and camptothecin-induced
apoptosis. YVAD-cmk and Z-VAD-fmk did not markedly affect
cytosolic or nuclear morphological effects of apoptosis induced by
OA (Figure 1E), although the nuclear chromatin condensation was
less pronounced and more patchy in the early apoptotic phase. The
Okadaic acid induced apoptosis and PAI-2 proteolysis 1687
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Figure 1 The phenotypic apoptotic morphologies induced by okadaic acid or
camptothecin in HL-60 cells are sensitive to inhibition by YVAD-cmk. The cells
were cultured in absence (A, D) or presence of 300 nM OA (OA) for 6 h (B, E)
or 5 mM camptothecin for 4 h (C, F). Some of the cells were supplemented with
300 mM YVAD-cmk (D, E, F). Micrographs show representative morphology of
the variously treated cells. The bar in panel F represents 1 mm
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Figure 2 OA-induced apoptotic nuclear chromatin condensation is not
affected by YVAD-cmk or Z-VAD-fmk. The cells were treated with 300 nM OA
(•), 300 nM OA and 300 mM YVAD-cmk (n), 300 nM OA and 100 mM Z-VAD-
fmk (u), 300 mM YVAD-cmk (n n), 100 mM Z-VAD-fmk (u u), or left
unsupplemented as control (l l). At regular time points cell aliquots were fixed
and stained with bisbenzimide, and the fraction of cells that had condensed
nuclear chromatin was determined. The bars show standard error of the
mean from three or more separate experimentspeptide protease inhibitors were found to counteract all morpho-
logical features of camptothecin-induced apoptosis including
condensation and fragmentation of nuclear chromatin (Figure 1F).
Specific degradation of chromosomal DNA was a prominent
feature of both OA- and camptothecin-induced cell death (Figure
4). YVAD-cmk counteracted the action of both agents rendering a
greater fraction of non-degraded chromosomal DNA, although the
internucleosomal DNA cleavage was not completely blocked.
YVAD-cmk did not induce spontaneous internucleosomal DNA
fragmentation at the concentrations used in the study (data not
shown).
Immunoblotting of cytosolic PAI-2 detected a 33 kDa PAI-2
fragment (Figure 5) with retained protease inhibition activity (data
not shown) during OA- and camptothecin-induced apoptosis in
HL-60 cells. The cleavage of PAI-2 during camptothecin-induced
apoptosis was an early event being detectable after 2 h of treat-
ment (Figure 5, lane 3). The PAI-2 cleavage induced by OA and
camptothecin was sensitive to the caspase I inhibitor YVAD-cmk
(Figure 5, lanes 5 and 7). As YVAD-cmk is an efficient inhibitor of
IL-1b-converting enzyme (ICE), we tested whether PAI-2 was a
substrate for ICE. In an in vitro assay, using pro-IL-1b as a posi-
tive control, recombinant PAI-2 was not found to be a substrate for
ICE (Figure 6, lanes 3 and 4).
OA- and camptothecin-induced commitment to cell
death is not retarded by YVAD-cmk
Induction of apoptosis is thought to proceed through a series of
steps, initially reversible, but inevitably becoming irreversible
leading to cell death. The time course for commitment to cell death
in HL-60 cells treated with OA or camptothecin was assessed
by determining the fraction surviving cells having normal
morphology 24 h after short periods of exposure to these agents
1688 PH Jensen et al
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Figure 3 Camptothecin-induced apoptotic nuclear chromatin condensation
is sensitive to inhibition by YVAD-cmk or Z-VAD-fmk. The cells were treated
with 5 mM camptothecin (•), 5 mM camptothecin and 300 mM YVAD-cmk (n), 5
mM camptothecin and 100 mM Z-VAD-fmk (u), 300 mM YVAD-cmk (n n), 100 mM
Z-VAD-fmk (u u), or left unsupplemented as control (l l). At regular time points
cell aliquots were fixed and stained with bisbenzimide, and the fraction of
cells that had condensed nuclear chromatin was determined. The bars show
standard error of the mean from 3–8 separate experiments. Inset: Potency of
protease inhibitors to inhibit camptothecin-induced nuclear chromatin
condensation. The cells were treated with 5 mM camptothecin in absence (•)
or presence of varying concentrations of YVAD-cmk (n), Z-VAD-fmk (u), or
left unsupplemented as control (l l). After treatment for 4 h, cell aliquots were
fixed and stained with bisbenzimide. The bars show standard error of the
mean from 3–5 separate experiments
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Figure 4 (A) Inhibition of OA- and camptothecin-induced internucleosomal
DNA fragmentation by YVAD-cmk. The cells were treated with 5 mM
camptothecin for 6 h (lanes 2 and 4) or 300 nM OA for 9 h (lanes 3 and 5).
The cultures shown in lanes 4 and 5 were supplemented with 300 mM
YVAD-cmk. Lane 1 represents control cells after 9 h. The size of the
internucleosomal DNA fragments was in the range 195–200 base pairs as
evidenced by the l-DNA reference marker (lane l). The extracted DNA was
subjected to agarose gel electrophoresis and the results from one
representative experiment shown. (B) The ratio of HMW DNA (above 8.5 kb)
versus LMW DNA (0.1–7.2 kb) was determined for each line 1–5 above as
outlined in Methods section(see Methods section for details). OA (300 nM) induced a swift
commitment to cell death; more than 50% of the cells were
doomed to death after 1.75 h of treatment. The commitment to cell
death by OA displayed a lag phase of about 1 h. During this time
period OA could be washed away without affecting the long-term
survival of the cells (Figure 7). No apparent time lag was noted for
camtothecin-induced apoptosis and the time course for commit-
ment to cell death was more protracted (Figure 7).
YVAD-cmk (300 mM) or Z-VAD-fmk (100 mM) did not affect
long-term survival of HL-60 cells (Figure 7). Although YVAD-cmk
(or Z-VAD-fmk) counteracted morphological effects of apoptosis,
inhibited internucleosomal DNA fragmentation and abolished PAI-
2 cleavage, the commitment to cell death by OA and camptothecin
was not retarded by co-treatment with YVAD-cmk (Figure 7).
DISCUSSION
Our data show that okadaic acid and camptothecin induce apop-
tosis with different morphological phenotypes (Figure 1). That one
single cell type can undergo different apoptotic phenotypes has
previously been shown in experimental studies (Gjertsen et al,
1994) and in studies on developmental cell death (Clarke, 1990).
Together these observations suggest that different regulatory
mechanisms are related to distinct cell death phenotypes. From a
therapeutic point of view this could be favourably, since resistance
against apoptosis involving one pathway, e.g. from loss of certain
caspase(s), can be overcome by triggering of apoptosis through
alternative pathways not dependent of the lacking caspase(s).
The role of caspase I in apoptosis is controversial (Nicholson
and Thornberry, 1997). Mice deficient in IL-1b (caspase I)
develop normally, suggesting a less important role of caspase I in
regulation of cell death during normal embryogenesis (Kuida et al,
1995). On the other hand, thymocytes from IL-1b-deficient mice
were found to be resistant to Fas-induced apoptosis showing an
impairment of the normal regulation of apoptosis in these cells
(Kuida et al, 1995). We report that YVAD-cmk, a potent inhibitor
of caspase I protease activity (Schumann et al, 1998), inhibits both
OA- and camptothecin-induced internucleosomal DNA degrada-
tion (Figure 4) and PAI-2 cleavage (Figure 5). However, only the
Okadaic acid induced apoptosis and PAI-2 proteolysis 1689
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Figure 5 Inhibition of OA- and camptothecin-induced selective PAI-2
cleavage by YVAD-cmk. Cells (0.5 ´ 106 per ml) were incubated in the
presence of 5 mM camptothecin for 1, 2, and 4 h respectively (lanes 2–5) or
300 nM OA for 9 h (lanes 6,7). Lane 1 represents untreated (control) cells
and lanes 5, 7 and 8 cells co-incubated with 300 mM YVAD-cmk. The cells
were extracted and processed by reducing 8–16% gradient SDS-PAGE, anti-
PAI-2 immunoblotting and ECL visualization as described in Methods
section. The estimated molecular weights, 43 kDa for native PAI-2 and
33 kDa for the PAI-2 cleavage product, respectively, are indicated
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Figure 6 Interleukin-1b-converting enzyme (ICE) does not cleave PAI-2 in
vitro. Recombinant human pro-IL-1b (30 mg ml-1; lanes 1–2) and recombinant
human PAI-2 (60 mg ml-1; lanes 3–4) were incubated in the absence (lanes
1, 3) or presence (lanes 2, 4) of recombinant ICE (3 mg ml-1) for 6 h. The
samples were processed by reducing 10–20% gradient SDS-PAGE, anti-IL-
1b immunoblotting and ECL detection as described in Methods section. The
molecular weight markers are indicated to the left
0.00
0.50
1.00
0.00
0.50
1.00
01234
3 mM Camptothecin
+ 300 mM YVAD
+ 100 mM ZVAD
+ 300 mM YVAD
+ 100 mM ZVAD
300 nM  OA
Hours of treatment
F
r
a
c
t
i
o
n
 
s
u
r
v
i
v
i
n
g
 
c
e
l
l
s
B
A
Figure 7 The time course for commitment to apoptosis induced by okadaic
acid or camtothecin is not prolonged by protease peptide inhibitors. (A). The
cells were treated with 5 mM camptothecin (•), 5 mM camptothecin and 300 mM
YVAD-cmk (n), 5 mM camptothecin and 100 mM Z-VAD-fmk (u), 300 mM
YVAD-cmk (n n), 100 mM Z-VAD-fmk (u u), or left unsupplemented as controls
(l l). (B) The cells were treated with 300 mM OA (•), 300 mM OA and 300 mM
YVAD-cmk (n), 300 nM OA and 100 mM Z-VAD-fmk (u), 300 mM YVAD-cmk
(n n), 100 mM Z-VAD-fmk (u u), or left unsupplemented as controls (l l). At times
indicated, cell aliquots were extensively washed (see Methods section),
reseeded, and cultured for the remaining time of a 24-h period. After 24 h of
culture the fraction of surviving cells was determined as the fraction of cells
having an intact (normal) non-condensed nuclear chromatin appearance.
The dying (apoptotic) cell fractions all show condensed and/or fragmented
nuclear chromatin. The bars show standard error of the mean from 3–5
separate experimentsphenotypic apoptotic morphology induced by camptothecin was
antagonized by YVAD-cmk and by Z-VAD-fmk (Figure 1–3), the
latter being a more broadly acting caspase inhibitor. The inhibition
of camptothecin-induced apoptosis by YVAD-cmk was observed
at concentrations above 30 mM and with a 50% inhibitory concen-
tration (IC50) of about 210 mM (Figure 3, inset). Knowing that the
inhibition constant for caspase I by YVAD-CHO is several orders
of magnitude lower than for inhibition of caspase 3 (Nicholson
and Thornberry, 1997) and that experiments in vitro have shown
IC50 for inhibition of IL-1b in the low mM range (Kuida et al,
1995), our results in vivo thus point to a role for a caspase I-related
activity in the execution phase of camptothecin and of OA-
mediated apoptosis in HL-60 cells.
A key object of this study has been to test whether caspase
inhibitors could modulate the time course for initiation (commit-
ment) of apoptosis by OA and camptothecin. The results were
conclusive on this point. Neither YVAD-cmk nor Z-VAD-fmk
were able to modulate the commitment to cell death by OA or
camptothecin. Additionally, treatment with YVAD-cmk or Z-
VAD-fmk had no adverse effect on HL-60 cell survival. Our
results are thus compatible with results in rat-1 fibroblast in which
the inhibition of ced-3/ICE-related proteases could not prevent cell
death induced by oncogenes, DNA damage or bak (a bcl-2 homo-
logue) although the execution phase of apoptosis was inhibited
(McCarthy et al, 1997). OA-treated cells showed a lag phase of
about 1 h during which time period the cells were fully non-
committed to cell death after removal of the drug (Figure 6). This
reversible lag period, corresponding to the induction time or lag
phase of apoptosis (Jakobson et al, 1994; Greenlund et al, 1995)
preparing the signal transduction machinery for cell suicide, was
not sensitive to caspase peptide inhibition. This observation
supports the idea that signalling pathways other than the cell death
proteases could be important for the regulation of the commitment
phase of OA-induced apoptosis. This is also supported by studies
in primary hepatocytes in which effects of serine/threonine protein
phosphatase inhibitors, including the induction of apoptosis, are
reversibly inhibited by antagonists of Ca2+/calmodulin-dependent
protein kinase type II (Mellgren et al, 1997; Toivola et al, 1997,
and unpublished observations).
In a previous communication we showed that PAI-2 was specif-
ically cleaved during OA-induced apoptotic cell death in a
promyelocytic leukaemic cell line (Jensen et al, 1994). This was,
to our knowledge, the first demonstration of selective proteolytic
cleavage of a putative cytoprotective cellular protease inhibitor
(Kumar and Baglioni, 1991). The time course for this cleavage,
whether associated with the induction/commitment or the execu-
tion phases of apoptotic cell death, has been tested in this study. In
OA-treated cells the time course for PAI-2 cleavage was associ-
ated with internucleosomal DNA degradation thus being linked to
the macromolecular degradation typical of the execution phase of
apoptosis (Figures 4 and 5). In camptothecin-treated cells the
cleavage of PAI-2 was an early event that accompanied other early
morphological effects of apoptosis like the membrane blebbing
and thus preceded the macromolecular degradation of DNA by
several hours. The cause for this difference in the timing of PAI-2
cleavage is not clear, but is supportive of the idea that OA- and
camptothecin-induced apoptosis involve partly divergent proteo-
lytic pathways. Also, whether this difference in time course for the
PAI-2 cleavage represents a cell-specific phenomenon or not,
remains to be clarified. PAI-2 was not found to be a substrate for
recombinant IL-1b (caspase 1) in vitro (Figure 6) although YVAD-
cmk inhibited camptothecin and OA mediated PAI-2 selective
cleavage in cells, and prevented caspase I-mediated cleavage of
pro-IL-1b in vitro (Figure 6). This led us to suggest that the PAI-2
cleavage should be mediated by some other apoptosis-associated
protease.
We report that the execution phase of OA- and camptothecin-
induced apoptosis in HL-60 cells was sensitive to protease
inhibitors selecting caspase I whereas the induction or commit-
ment phase was not. Our data suggest that diverse proteolytic
mechanisms are involved in the execution phase of OA and
camptothecin, some being sensitive to caspase I-related inhibition,
others not. Moreover, the results are focused on the degradation of
PAI-2, a putative cytoprotective protease inhibitor, in relation to
the commitment and execution phases of OA- and camptothecin-
induced apoptosis in HL-60 cells.
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